RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105

RBC Capital analyst Kendall Au has maintained an 'Outperform' rating on DexCom (NASDAQ: DXCM) and increased the price target from $90 to $105. This adjustment reflects a positive outlook on the company's performance.